You know your biopharmaceutical product has a global impact! Your global launch strategy will make all the difference when it comes to success or failure for your company, your stakeholders and ultimately the patients you serve. Choosing the right local partner is crucial to your global launch. From location to R&D or clinical trials and production, from licensing to stand-alone launch---understanding the regulatory maze can determine when and where you launch.
Join our webinar on Wednesday, May 29 at 12pm EDT (9 am PDT / 6 pm CEST) to hear from one of the leading experts in Europe, Dr. Maria Heimgartner, Managing Director of regulanet® Switzerland GmbH and former General Manager of Genzyme Switzerland as she and Douglas Ebert, Senior Advisor, Greater Zurich Area Ltd (GZA) discuss "How to navigate the regulatory maze".
What you will learn:
- An overview of the life science ecosystem in the Greater Zurich Area in Switzerland
- How to "run the gauntlet" with European regulators
- Mitigating launch risks by understanding the complexity of the European regulatory environment
|Dr. Maria Heimgartner
CEO of regulanet® Switzerland GmbH. Since 2012, she has practiced as a principal consultant at Target BioScience. Previously, she served 8 years as General Manager for Genzyme Switzerland and 8 years as Business Unit Manager at Schering Plough. Maria brings over 15 years of experience in the pharmaceutical industry and holds a PhD in Biology from the University of Munich and Bachelor of Science from the University of Houston, Texas.
|Douglas Karl Ebert
Senior Advisor Americas for Greater Zurich Area Ltd (GZA). He has over 25 years of experience in the field of international economic development and foreign direct investment, including engagements with a number of cantonal and regional development agencies in Switzerland as well as state governments. Prior to his work in economic development, Douglas Ebert specialized in work-force development as Vice President of Consulting and Client Services for an international outplacement firm.
A congress for scientists from academia and industry to present their projects to potential partners and investors.
Independent investor conference focused on publicly traded and select private biotech companies
One of the largest comprehensive trade shows for unmanned and autonomous systems.